McKesson announces changes to reportable segments, organizational structure

McKesson (MCK) on Thursday announced changes to its reportable segments and organizational structure, effective in the second quarter of fiscal year 2026. The new reporting structure enhances strategic alignment and transparency, supporting optimizing portfolio management to drive sustainable long-term value creation for shareholders, the company said in a statement. Britt Vitalone, CFO, said: “This updated reporting structure reflects a strategic evolution of our business – accelerating growth in the high-margin areas of oncology, multispecialty, and biopharma services. It enhances transparency and reinforces our disciplined approach to capital allocation and shareholder value creation.” The new reportable segments are: North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, Medical-Surgical Solutions, and Other.